Home > Search Results

About - Budesonide

By breathing: Prevents asthma attacks. This medicine is a steroid.

By mouth: Treats Crohn disease and ulcerative colitis. This medicine is a corticosteroid.

Into the nose: Treats an itchy or runny nose, sneezing, or other symptoms caused by hay fever (allergic rhinitis). This medicine is a steroid (cortisone-like medicine).

UsesSide effectsLatest evidence reviewsResearch summaries for consumersBrand names

Results: 1 to 20 of 147

Efficacy and safety of budesonide for collagenous colitis: a meta-analysis

Bibliographic details: Peng C, Lv Y, Li Y, Xu Z, Zou X.  Efficacy and safety of budesonide for collagenous colitis: a meta-analysis. Chinese Journal of Gastroenterology 2010; 15(8): 478-482 Available from: http://d.wanfangdata.com.cn/periodical_wcbx201008008.aspx

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

The effectiveness and safety of ciclesonide versus fluticasone, budesonide, and beclomethasone in treatment of persistent asthma: a comprehensive review of literature

Bibliographic details: Zali Z, Akbari-Sari A, Yazdizadeh B, Hosseini A, Tabatabaei SA.  The effectiveness and safety of ciclesonide versus fluticasone, budesonide, and beclomethasone in treatment of persistent asthma: a comprehensive review of literature. Journal of Isfahan Medical School 2014; 32(278): 342-358 Available from: http://www.jims.mui.ac.ir/index.php/jims/article/view/2847/6186

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Effects of topical administration of budesonide and traditional glucocorticosteroids on active distal ulcerative colitis or proctitis

Bibliographic details: Huang M-L, Ran Z-H, Tong J-L, Lu L-H, Xiao S-D.  Effects of topical administration of budesonide and traditional glucocorticosteroids on active distal ulcerative colitis or proctitis. World Chinese Journal of Digestology 2008; 16(3): 326-331

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

Meta-analysis: budesonide treatment for collagenous colitis

BACKGROUND: Collagenous colitis is typified by chronic watery diarrhoea and characteristic histological alterations of the colonic mucosa without endoscopic abnormalities. Budesonide, a corticosteroid with high first-pass metabolism has been examined in collagenous colitis, but studies to date have had small numbers, and relatively low statistical power.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2004

Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis

The aim of this study was to examine the dose-response relationship of inhaled budesonide in adolescents and adults with asthma. A meta-analysis was carried out on placebo-controlled, randomised clinical trials, presenting data on at least one outcome measure of asthma and using at least two doses of budesonide, delivered by turbuhaler or metered-dose inhaler + spacer twice daily. A total of six studies of 1,435 adolescents and adults, with mild to moderately severe asthma, met the inclusion criteria for the meta-analysis. A negative exponential model indicated that 80% of the benefit at 1,600 micrograms.day-1 was achieved at doses of approximately 200-400 micrograms.day-1 and 90% by 300-600 micrograms.day-1. Meta-regression with a quadratic term in dose showed that the maximum effect was obtained with doses of approximately 1,000 micrograms.day-1. In conclusion, the available published data indicate that, in adolescents and adults with mild to moderate asthma, most of the therapeutic benefit of budesonide delivered by turbuhaler or metered-dose inhaler + spacer is achieved with a dose of approximately 400 micrograms.day-1 and the maximum effect is achieved at approximately 1,000 micrograms.day-1. This conclusion is qualified by the recognition that there is considerable individual variability in the response to inhaled corticosteroids and that the subjects included in this meta-analysis had predominantly mild to moderate asthma.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2004

Prednisolone and budesonide for short- and long-term treatment of microscopic colitis: systematic review and meta-analysis

BACKGROUND & AIMS: The incidence of microscopic colitis and its disease burden are increasing, yet there is limited systematic information addressing the use of conventional corticosteroids and budesonide in microscopic colitis. We performed a systematic review and meta-analysis on the short- and long-term efficacy of corticosteroids in treatment of microscopic colitis.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

Budesonide versus placebo for asthma

Budesonide is highly effective preventative treatment for all patients with asthma, irrespective of age or severity of their disease. Most benefits are seen with low‐moderate doses.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2008

The effects of beclomethasone or budesonide for chronic asthma

Beclomethasone and budesonide are commonly used to treat people with asthma in the long‐term. Despite the large amount of research which has been conducted with these two steroids, very little can be concluded as to how effective they are, because the quality of the research to date has not been strong enough. The available research does not therefore provide a clear answer as to whether beclomethasone or budesonide are better for treating asthma.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2015

Systematic review and meta-analysis of budesonide/formoterol in a single inhaler

OBJECTIVE: To compare the effectiveness of budesonide/formoterol using fixed dosing (BUD/FORM) with inhaled corticosteroid (ICS) alone or alternative ICS and long-acting beta(2)-agonist (LABA) regimens for adults with moderate/severe asthma.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2007

Formoterol and budesonide for the relief of asthma symptoms in adults and children

Combined formoterol and budesonide inhalers can be used for maintenance treatment of asthma and relief of symptoms. Three trials involving 5905 participants were included. We found very little evidence in relation to the use of formoterol and budesonide for relief of symptoms in people with mild asthma, but in people with more severe asthma who had suffered exacerbations in spite of regular treatment with inhaled corticosteroids, we found that reliever formoterol and budesonide compared favourably with terbutaline in reducing asthma exacerbations that required a course of oral corticosteroids. However only a small proportion of the 'severe asthma exacerbations' as defined in the trials led to hospital admissions, and no significant overall benefit has yet been shown for this outcome. In children with asthma that was not controlled with regular inhaled corticosteroids, there were fewer serious adverse events when formoterol and budesonide were used to relieve symptoms as well as for maintenance treatment.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2013

Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children

This review compares the effectiveness of three inhaled steroids. Fluticasone (FP) was compared with either beclomethasone (BDP) or budesonide (BUD) for treating people with chronic asthma. When FP was given to children or adults at approximately half the daily dose of either BDP or BUD, it appeared to be at least as effective as the other two drugs in improving airway opening. There was not enough information available to draw conclusions concerning the effect of these drugs on symptoms, or the risk of an acute asthma exacerbation. When given at the same dose as BDP or BUD, FP treated participants had slightly better lung function. However, at the same dose FP was also associated with increased hoarseness, although it did not lead to increased incidences of other side‐effects associated with steroids such as oral thrush or sore throat.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2009

Budesonide for treatment of active Crohn's disease

Traditional corticosteroids are often used as treatment for active Crohn's disease. Unfortunately, corticosteroids can cause side effects. Budesonide is a newer corticosteroid drug which is quickly metabolized by the liver thereby reducing corticosteroid related side effects. Budesonide is more effective than placebo (fake medicine) or mesalamine for the treatment of active Crohn's disease. Traditional corticosteroids are more effective than budesonide for the treatment of active Crohn's disease, particularly in patients with severe disease. However, budesonide is less likely than traditional corticosteroids to cause side effects.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2009

Budesonide at different doses for asthma

Budesonide is an inhaled corticosteroid used to treat the inflammation of airways (passages to the lungs) that occurs in asthma. This review presents the effects of budesonide at different doses for people with varying degrees of asthma. In patients with mild‐moderate asthma no important differences were apparent between the lowest dose (200 mcg/d) and the highest dose (1600 mcg/d) for measures of airway opening and symptoms. However, patients with more severe asthma are less likely to experience an acute worsening of their asthma control when a higher dose (1600 mcg/d) is used regularly compared to a lower dose (200 mcg/d). Future research should report results more comprehensively, and should use quality of life questionnaires.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2008

Different combinations of inhaled steroids and long‐acting beta‐agonists for chronic asthma (fluticasone/salmeterol versus budesonide/formoterol)

People with persistent asthma often require an additional treatment to regular inhaled steroids. Some preparations of long‐acting beta‐agonists are delivered in the same inhaler device as the inhaled corticosteroids. Inhaled steroids help to treat inflammation of the airway and long‐acting beta‐agonists help the airway to relax, improving symptoms and lung function. This systematic review examined randomised controlled trials comparing two commonly available combinations administered at a fixed dose through a single inhaler, fluticasone/salmeterol and budesonide/formoterol. We included five studies which recruited 5537 people. The trials were generally well designed but only recruited adults and adolescents and not children. Participants were already taking regular inhaled steroids before the studies commenced and had mild or moderate asthma based on tests of their airway. We found that the number of people who required treatment with oral steroids and admission to hospital was similar between the treatments, but due to the statistical uncertainty of this result we could not rule out important differences in favour of either drug combination. Additional trials would enable us to draw more reliable conclusions about how well these drugs work compared with each other. We also looked at serious adverse events. Again, the results did not indicate that one combination was clearly better than the other, but again these results were imprecise so we cannot be certain. However, lung function and rescue medication use were similar between the treatments. We could not assess the relative effects of these drugs on mortality because there were so few deaths which leads to statistical uncertainty; out of the five studies, one person died. Quality of life was measured in different ways in two studies and we could not determine how the treatments compared in this respect. Further studies are needed to strengthen and better explain these findings. In particular studies which assess the effects of these therapies in children and studies which measure quality of life are a priority.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2012

Budesonide once versus twice-daily administration: meta-analysis

This review compared budesonide given once versus twice daily for the treatment of asthma. The authors concluded that once-daily administration had similar efficacy to twice-daily administration for the treatment of mild to moderate asthma. However, the lack of a validity assessment threatens the reliability of the authors' conclusion.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2004

Budesonide and the risk of pneumonia: a meta-analysis of individual patient data

The review assessed the effects of inhaled budesonide on the risk of pneumonia in patients with chronic obstructive pulmonary disorder. The authors concluded that budesonide treatment did not increase the risk of pneumonia and was safe. The small number of events in the analyses, coupled with limitations in review methodology, means the authors' conclusions should be interpreted with caution.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Oral budesonide for the treatment of ulcerative colitis

Inflammatory bowel disease consists of 2 main subtypes; ulcerative colitis (UC) and Crohn's disease (CD). Ulcerative colitis is a chronic, relapsing and remitting, inflammatory condition affecting the large bowel. Traditional corticosteroids are often used in the treatment of moderate to severe, active UC. However, traditional corticosteroids are associated with a wide range of side‐effects. Budesonide is a steroid, but it is rapidly metabolized by the body and therefore has less side‐effects than traditional corticosteroids. We know that oral budesonide has a role in the treatment of some patients with CD and it has also shown beneficial effects when used as an enema for UC, when only the distal colon is involved. The purpose of this review was to examine the effectiveness of oral budesonide for the treatment of UC. We found three studies that were eligible for inclusion in this review. Although the side‐effect profile of budesonide is better than that of prednisolone, there is no evidence to recommend the use of oral budesonide for active UC. There are 2 large ongoing trials which will provide further information regarding the potential effectiveness of oral budesonide for the treatment of active UC. One of the included studies compared budesonide with mesalamine (a 5‐ASA drug). This study provides high quality evidence that mesalamine is superior to budesonide for the treatment of active ulcerative colitis.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2011

In people with asthma are single inhalers that contain both formoterol and budesonide better than current best practice?

‘Single inhaler therapy’ means that a single inhaler containing two drugs is used. One of these drugs acts quickly and is called the "reliever". The other works much more slowly and is called the "preventer". The reliever is a beta‐agonist bronchodilator, which help to open the airways and help people breathe more easily. The preventer is a steroid that controls the underlying inflammation in the lungs, which is caused by the asthma. People on 'single inhaler therapy' (SiT) have one inhaler for use every day to control their underlying inflammation and also for symptom relief. The idea behind SiT is that when people take their inhalers to reduce their shortness of breath or wheezing they will also be getting an increased dose of the steroid preventer.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2013

Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review

This review evaluated ciclesonide and alternative inhaled corticosteroids for asthma in adults. It concluded that there is limited evidence that inhaled ciclesonide has similar effectiveness and efficacy to fluticasone and budesonide, but no clear evidence on side-effects. The conclusions about limited evidence seem reliable; further data may become available when identified studies reported as abstracts are published in full.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2006

Ciclesonide compared to budesonide and fluticasone in the treatment of asthma in children

Asthma is a common disease in childhood. Most children with chronic asthma are treated with inhaled corticosteroids (ICS) to control airway inflammation and reduce asthma symptoms. Although these drugs are considered to be very safe and effective, not all children achieve full asthma control and some parents are concerned about the possibility of reduced growth or local side effects such as hoarseness. The challenge for newer ICS is to achieve improved asthma control with fewer side effects. This could be achieved by small‐particle‐size ICS, leading to better lung deposition as they penetrate deeper into the small airways. Therefore, asthma control could be achieved with lower daily doses and with fewer side effects. In children, particle size of ICS might be even more important because of their smaller airways.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2013

Systematic Reviews in PubMed

See all (236)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...